CoAptus Medical
Stage
Unattributed | AliveTotal Raised
$3MLast Raised
$3M | 14 yrs agoMissing: CoAptus Medical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: CoAptus Medical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
CoAptus Medical Patents
CoAptus Medical has filed 6 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/6/2008 | 11/13/2012 | Catheters, Interventional radiology, Geosocial networking, Endoscopy, Geolocation | Grant |
Application Date | 10/6/2008 |
|---|---|
Grant Date | 11/13/2012 |
Title | |
Related Topics | Catheters, Interventional radiology, Geosocial networking, Endoscopy, Geolocation |
Status | Grant |
CoAptus Medical Frequently Asked Questions (FAQ)
Where is CoAptus Medical's headquarters?
CoAptus Medical's headquarters is located at 14963 NE 95th ST, Redmond.
What is CoAptus Medical's latest funding round?
CoAptus Medical's latest funding round is Unattributed.
How much did CoAptus Medical raise?
CoAptus Medical raised a total of $3M.
Who are CoAptus Medical's competitors?
Competitors of CoAptus Medical include JenaValve, InterRad Medical, Respicardia, VasoNova, Xoft and 11 more.
Compare CoAptus Medical to Competitors
JenaValve develops, manufactures, and markets transcatheter aortic valve implantation systems (TAVI) to treat patients suffering from aortic valve disease. The company's transapical aortic valve system is CE-marked and currently marketed in Europe and other markets worldwide. The company was founded in 2006 and is based in Irvine, California.
CardioMetrix is a medical device company developing implantable technologies to assist physicians in managing patients suffering from congestive heart failure (CHF).
CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.
CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.
Chase Medical is developing medical technology for treating congestive heart failure. Chase Medical is developing a device called the Mannequin which aims to help the heart maintain its shape while going through reconstruction of the left ventricle.
Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.